当前的丁型肝炎状况。
Current status of hepatitis delta.
机构信息
University College of London, Institute of Liver and Digestive Health, Royal Free Campus, London, UK.
Department of Gastroenterology, Medical School of National and Kapodistrian University of Athens, General Hospital of Athens "Laiko", Athens, Greece.
出版信息
Curr Opin Pharmacol. 2021 Jun;58:62-67. doi: 10.1016/j.coph.2021.03.008. Epub 2021 Apr 22.
Hepatitis D virus (HDV) infection in patients chronically infected with hepatitis B virus (HBV) causes the most severe form of chronic viral hepatitis and continues to represent a major health problem. The latest data show that the global prevalence is much higher than previously considered. Therefore, screening with the detection of anti-HDV antibodies is mandatory for all chronic HBV patients. In spite of the severity of liver disease, the only recommended treatment today is pegylated interferon-alpha, which has limited efficacy. Novel host-targeting molecules are now under investigation. The current phase 2 clinical trials include pegylated interferon-lambda, bulevirtide, lonafarnib, and REP-2139. This review focuses on the current status of epidemiology, diagnosis, and treatment of HDV infection.
丁型肝炎病毒（HDV）感染慢性乙型肝炎病毒（HBV）感染者可导致最严重的慢性病毒性肝炎，且仍然是一个主要的健康问题。最新数据显示，其全球流行率远高于先前的估计。因此，对所有慢性 HBV 患者进行抗-HDV 抗体检测筛查是强制性的。尽管肝脏疾病严重，目前唯一推荐的治疗方法是聚乙二醇干扰素-α，但疗效有限。新型宿主靶向分子正在研究中。目前的 2 期临床试验包括聚乙二醇干扰素-λ、替诺福韦、洛那法尼和 REP-2139。本文综述了 HDV 感染的流行病学、诊断和治疗现状。
Zotero 插件